Skip to main content

Advertisement

SpringerLink
Log in

Anaphylaxis Induced by Biologics

  • Anaphylaxis (M Sanchez-Borges, Section Editor)
  • Published:
Current Treatment Options in Allergy Aims and scope Submit manuscript

Abstract

Purpose of review

Biologic agents are increasingly utilized in the medical management of many conditions. Their safety has become an important topic as a myriad of reactions can occur due to the immune-modulating properties of these agents. Of these, anaphylaxis remains a substantial concern, but its incidence and pathophysiology have not been comprehensively reviewed.

Recent findings

Over the past two decades, a multitude of case reports and series have been published describing anaphylactic reactions to biologic agents, although the true incidence and prevalence remains unknown for the vast majority of them. Based on cytokine and mediator profiles, three mechanisms have been proposed: IgE-mediated, non-IgE-mediated, and cytokine release.

Summary

The clinical presentation of anaphylaxis is highly variable between biologic agents. The degree of humanization, excipient involvement, and development process of each biologic agent all likely play an important role in determining its level of allergenicity. As biologic agents become even more commonplace in healthcare, more thorough evaluations of the incidence of anaphylaxis induced by BAs as well as the underlying mechanisms may provide clinically useful data when determining the most appropriate management option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Food and Drug Administration (2018) Biological Approvals by Year. https://www.fda.gov/biologicsbloodvaccines/developmentapprovalprocess/biologicalapprovalsbyyear/default.htm. Accessed 11/2/2018.

  2. Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61(8):912–20. https://doi.org/10.1111/j.1398-9995.2006.01058.

    Article  CAS  PubMed  Google Scholar 

  3. Hausmann OV, Seitz M, Villiger PM, Pichler WJ. The complex clinical picture of side effects to biologicals. Med Clin North Am. 2010;94(4):791–804. https://doi.org/10.1016/j.mcna.2010.03.001.

    Article  CAS  PubMed  Google Scholar 

  4. Lieberman P, Nichklas RA, Randolph C, Oppenheimer J, Bernstein D, Bernstein J, et al. Anaphylaxis – a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341–84. https://doi.org/10.1016/j.anai.2015.07.019.

    Article  PubMed  Google Scholar 

  5. Wood RA, Camargo CA Jr, Lieberman P, Sampson HA, Schwartz LB, Zitt M, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(2):461–7. https://doi.org/10.1016/j.jaci.2013.08.016.

    Article  PubMed  Google Scholar 

  6. Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014;134(6):1318–1328.e7. https://doi.org/10.1016/j.jaci.2014.08.018.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Vultaggio A, Castells MC. Hypersensitivity reactions to biologic agents. Immunol Allergy Clin N Am. 2014;34:615–32.

    Article  Google Scholar 

  8. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84. https://doi.org/10.1002/art.23721.

    Article  CAS  PubMed  Google Scholar 

  9. Abramowicz D, Crusiaux A, Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med. 1992;327(10):739.

    Google Scholar 

  10. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373–7.

    Article  CAS  Google Scholar 

  11. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;38(11):1109–17. https://doi.org/10.1056/NEJMoa074943.

    Article  Google Scholar 

  12. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98(6):1315–24.

    Article  CAS  Google Scholar 

  13. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259–66. https://doi.org/10.1016/j.jaci.2009.09.009.

    Article  CAS  PubMed  Google Scholar 

  14. Wong JT, Long A. Rituximab hypersensitivity: evaluation, desensitization, and potential mechanisms. J Allergy Clin Immunol Pract. 2017;5(6):1564–71. https://doi.org/10.1016/j.jaip.2017.08.004.

    Article  PubMed  Google Scholar 

  15. Corominas M, Gastaminza G, Lobera T. Hypersensitivity reactions to biological drugs. J Investig Allergol Clin Immunol. 2014;24(4):212–25.

    CAS  PubMed  Google Scholar 

  16. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007;28(3):313–9.

    Article  CAS  Google Scholar 

  17. Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol. 2007;120(3):506–15.

    Article  CAS  Google Scholar 

  18. Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. 2008;358(1):2–35. https://doi.org/10.1056/NEJMoa070030.

    Article  Google Scholar 

  19. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010;65(5):657–61. https://doi.org/10.1111/j.1398-9995.2009.02280.x.

    Article  CAS  PubMed  Google Scholar 

  20. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford). 2007;46(12):1828–34.

    Article  CAS  Google Scholar 

  21. Subramanian H, Gupta K, Ali H. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J Allergy Clin Immunol. 2016;138(3):700–10. https://doi.org/10.1016/j.jaci.2016.04.051.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015;519(7542):237–41. https://doi.org/10.1038/nature14022.

    Article  CAS  PubMed  Google Scholar 

  23. Grimbaldeston MA. Mast cell-MrgprB2: sensing secretagogues or means to overreact? Immunol Cell Biol. 2015;93(3):221–3. https://doi.org/10.1038/icb.2015.10.

    Article  CAS  PubMed  Google Scholar 

  24. Todd PA, Brogden RN. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989;37(6):871–99.

    Article  CAS  Google Scholar 

  25. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996;51(5):865–94.

    Article  CAS  Google Scholar 

  26. Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009;5(5):499–521. https://doi.org/10.1586/eci.09.31.

    Article  CAS  PubMed  Google Scholar 

  27. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007;11(1 Suppl):37–42.

    Article  Google Scholar 

  28. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601–9.

    Article  CAS  Google Scholar 

  29. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(14):2311–9. https://doi.org/10.1200/JCO.2007.13.1193.

    Article  CAS  PubMed  Google Scholar 

  30. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456–73.

    Article  CAS  Google Scholar 

  31. •• Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142(1):159–70. https://doi.org/10.1016/j.jaci.2018.02.018. This study descibes and classifies hypersensitivity reactions in a novel evidence - based classification systems as well as reviews effectiveness of desensitization.

  32. Vasquez EM, Fabrega AJ, Pollak R. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity. Transplant Proc. 1995;27(1):873–4.

    CAS  PubMed  Google Scholar 

  33. Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De Pauw L, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 1989;47(4):606–8.

    Article  CAS  Google Scholar 

  34. Werier J, Cheung AH, Matas AJ. Anaphylactic hypersensitivity reaction after repeat OKT3 treatment. Lancet. 1991;337(8753):1351.

    Article  CAS  Google Scholar 

  35. Georgitis JW, Browning MC, Steiner D, Lorentz WB. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy. 1991;66(4):343–7.

    CAS  PubMed  Google Scholar 

  36. Norman DJ, Shield CF III, Henell KR, Kimball J, Barry JM, Bennett WM, et al. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. Transplantation. 1988;46(4):523–9.

    Article  CAS  Google Scholar 

  37. Lee CW, Logan JL, Zukoski CF. Cardiovascular collapse following orthoclone OKT3 administration: a case report. Am J Kidney Dis. 1991;17(1):73–5.

    Article  CAS  Google Scholar 

  38. Berkowitz RJ, Possidente CJ, McPherson BR, Guillot A, Braun SV, Reese JC. Anaphylactoid reaction to muromonab-CD3 in a pediatric renal transplant recipient. Pharmacotherapy. 2000;20(1):100–4.

    Article  CAS  Google Scholar 

  39. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45.

    Article  CAS  Google Scholar 

  40. O’Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007;25(24):3644–8.

    Article  Google Scholar 

  41. Keating K, Walko C, Stephenson B, O’Neil BH, Weiss J. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital. J Oncol Pharm Pract. 2014;20(6):409–16. https://doi.org/10.1177/1078155213510542.

    Article  CAS  PubMed  Google Scholar 

  42. Chitnavis M, Stein DJ, Commins S, Schuyler AJ, Behm B. First-dose anaphylaxis to infliximab: a case of mammalian meat allergy. J Allergy Clin Immunol Pract. 2017;5(5):1425–6. https://doi.org/10.1016/j.jaip.2017.04.044.

    Article  PubMed  Google Scholar 

  43. • Steinke JW, Platts-Mills TA, Commins SP. The alpha-gal story: lessons learning from connecting the dots. J Allergy Clin Immunol. 2015;135(3):589–96. https://doi.org/10.1016/j.jaci.2014.12.1947. Excellent review of the connection between biologics and alpha-gal sensitivity.

  44. Lammerts van Bueren JJ, Rispens T, Verploegen S, van der Palen-Merkus T, Stapel S, Workman LJ, et al. Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol. 2011;29:574–6.

    Article  CAS  Google Scholar 

  45. Reichert JM. Marketed therapeutic antibodies compendium. MAbs. 2012;4(3):413–5. https://doi.org/10.4161/mabs.19931.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Weiss J, Grilley Olson J, Deal AM, Chera B, Weissler M, Murphy BA, et al. Using the galactose-alpha-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab. Cancer. 2016;122(11):1697–701. https://doi.org/10.1002/cncr.29978.

    Article  CAS  PubMed  Google Scholar 

  47. Dupont B, Mariotte D, Dugue AE, Clarisse B, Grellard JM, Babin E, et al. Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab. Br J Clin Pharmacol. 2017;83(3):623–31. https://doi.org/10.1111/bcp.13140.

    Article  CAS  PubMed  Google Scholar 

  48. Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8.

    Article  CAS  Google Scholar 

  49. Matucci A, Pratesi S, Petroni G, Nencini F, Virgili G, Milla M, et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy. 2013;43(6):659–64. https://doi.org/10.1111/cea.12098.

    Article  CAS  PubMed  Google Scholar 

  50. Hwang SH, Yoo HS, Yoon MK, Park HS. Detection of IgE binding component to infliximab in a patient with infliximab-induced anaphylaxis. Ann Allergy Asthma Immunol. 2014;112(4):393–4. https://doi.org/10.1016/j.anai.2014.02.001.

    Article  CAS  PubMed  Google Scholar 

  51. Vultaggio A, Matucci A, Nencini F, Pratesi S, Maggi E. Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. Intern Emerg Med. 2012;(Suppl 2):S77–9. https://doi.org/10.1007/s11739-011-0611-x.

  52. Puxeddu I, Giori L, Rocchi V, Bazzichi L, Bombardieri S, Tavoni A, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol. 2012;108(2):123–4. https://doi.org/10.1016/j.anai.2011.11.004.

    Article  PubMed  Google Scholar 

  53. Quismorio A, Brahmbhatt B, Houng M, Panush RS. Etanercept allergy and anaphylaxis. J Rheumatol. 2012;39(11):2225–6. https://doi.org/10.3899/jrheum.120791.

    Article  PubMed  Google Scholar 

  54. Houtman PM, Jansen TL, Blanken R. Anaphylactic reaction in a patient with rheumatoid arthritis: a rare side effect of methotrexate with etanercept as a provoking factor? J Clin Rheumatol. 2006;12(6):321–2.

    Article  Google Scholar 

  55. Quercia O, Emiliani F, Foschi FG, Stefanini GF. Adalimumab desensitization after anaphylactic reaction. Ann Allergy Asthma Immunol. 2011;106(6):547–8.

    Article  Google Scholar 

  56. Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol. 2007;7(5):393–403.

    Article  CAS  Google Scholar 

  57. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. 2007;120(6):1378–81.

    Article  CAS  Google Scholar 

  58. Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study. J Allergy Clin Immunol. 2016;138(3):913–5. https://doi.org/10.1016/j.jaci.2016.03.030.

    Article  CAS  PubMed  Google Scholar 

  59. Lieberman PL, Jones I, Rajwanshi R, Kosen K, Umetsu DT. Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics. J Allergy Clin Immunol. 2017;140(6):1734–6. https://doi.org/10.1016/j.jaci.2017.07.013.

    Article  PubMed  Google Scholar 

  60. Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts-Mills T, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol. 2011;128(1):210–2. https://doi.org/10.1016/j.jaci.2011.04.010.

    Article  PubMed  Google Scholar 

  61. Patel SV, Khan DA. Adverse reactions to biologic therapy. Immunol Allergy Clin N Am. 2017;37(2):397–412. https://doi.org/10.1016/j.iac.2017.01.012.

    Article  Google Scholar 

  62. Lieberman P, Rahmaoui A, Wong DA. The safety and interpretability of skin tests with omalizumab. Ann Allergy Asthma Immunol. 2010;105(6):493–5. https://doi.org/10.1016/j.anai.2010.10.008.

    Article  PubMed  Google Scholar 

  63. Kelso JM. Omalizumab anaphylaxis occurring outside the recommended observation times. J Allergy Clin Immunol. 2017;139(5):1718. https://doi.org/10.1016/j.jaci.2016.12.977.

    Article  PubMed  Google Scholar 

  64. Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058–70. https://doi.org/10.1016/j.clinthera.2016.07.010.

    Article  CAS  PubMed  Google Scholar 

  65. Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y, Garin M, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5(6):1572–81. https://doi.org/10.1016/j.jaip.2017.08.024.

    Article  PubMed  Google Scholar 

  66. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207. https://doi.org/10.1056/NEJMoa1403290.

    Article  CAS  PubMed  Google Scholar 

  67. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–98. https://doi.org/10.1016/j.chest.2016.03.032.

    Article  PubMed  Google Scholar 

  68. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicenter, parallel, double-blind, randomized, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66. https://doi.org/10.1016/S2213-2600(15)00042-9.

    Article  CAS  PubMed  Google Scholar 

  69. Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017;5(7):568–76. https://doi.org/10.1016/S2213-2600(17)30190-X.

    Article  CAS  PubMed  Google Scholar 

  70. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–41. https://doi.org/10.1016/S0140-6736(16)31322-8.

    Article  CAS  PubMed  Google Scholar 

  71. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomized, multicenter, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–27. https://doi.org/10.1016/S0140-6736(16)31324-1.

    Article  CAS  PubMed  Google Scholar 

  72. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomized, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303. https://doi.org/10.1016/S0140-6736(17)31191-1.

    Article  CAS  Google Scholar 

  73. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.

    Article  CAS  Google Scholar 

  74. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. https://doi.org/10.1016/S0140-6736(16)30307-5.

    Article  CAS  Google Scholar 

  75. Rituxan (rituximab) [Package insert]. South San Francisco: Genentech Inc; 1997.

  76. Piva E, Chieco-Bianchi F, Krajcar V, Aversa S, Plebani M. Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: in vitro evaluation of rituximab hypersensitivity by basophil activation test. Am J Hematol. 2012;87(11):E130–1. https://doi.org/10.1002/ajh.23329.

    Article  CAS  PubMed  Google Scholar 

  77. Beckman DB, Mathisen TL, Harris KE, Boxer MB, Grammer LC. Hypersensitivity to IFN-alpha. Allergy. 2001;56(8):806–7.

    Article  CAS  Google Scholar 

  78. Pardini S, Bosincu L, Bonfigli S, Dore F, Longinotti M. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon. Acta Haematol. 1991;85(4):220.

    Article  CAS  Google Scholar 

  79. Kendirli T, Kismet E, Demirkaya E, Aydin HI, Kesik V, Köseoğlu V. Death possibly associated with interferon use in a patient with chronic hepatitis. Acta Paediatr. 2005;94(7):984–5.

    Article  Google Scholar 

  80. Corona T, Leon C, Ostrosky-Zeichner L. Severe anaphylaxis with recombinant interferon beta. Neurology. 1999;52(2):425.

    Article  CAS  Google Scholar 

  81. Mazzeo L, Ricciardi L, Fazio MC, Fogliani O, Fedele R, Ferlazzo E, et al. Severe urticaria due to recombinant interferon beta-1a. Br J Dermatol. 2003;148(1):172.

    Article  CAS  Google Scholar 

  82. Brown DL, Login IS, Borish L, Powers PL. An urticarial IgE-mediated reaction to interferon beta-1b. Neurology. 2001;56(10):1416–7.

    Article  CAS  Google Scholar 

  83. Abraham D, McGrath KG. Hypersensitivity to aldesleukin (interleukin-2 and proleukin) presenting as facial angioedema and erythema. Allergy Asthma Proc. 2003;24(4):291–4.

    PubMed  Google Scholar 

  84. Batel-Copel L, Mommeja-Marin H, Oudard S, Chauvenet L, Pujade-Lauraine E, Coupier J, et al. Anaphylactic reaction after a first filgrastim (granulocyte-colony stimulating factor) injection. Eur J Cancer. 2428;31A(13–14):1995.

    Google Scholar 

  85. Jaiyesimi I, Giralt SS, Wood J. Subcutaneous granulocyte colony-stimulating factor and acute anaphylaxis. N Engl J Med. 1991;325(8):587.

    CAS  PubMed  Google Scholar 

  86. Tsavaris N, Polyzos A, Kosmas C, Giannikos L, Gogas J. A feasibility study of 1-h paclitaxel infusion in patients with solid tumors. Cancer Chemother Pharmacol. 1997;40(4):353–7.

    Article  CAS  Google Scholar 

  87. Khoury H, Adkins D, Brown R, Vij R, Westervelt P, Trinkaus K, et al. Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000;25(11):1197–201.

    Article  CAS  Google Scholar 

  88. Tulpule S, Shaw BE, Makoni P, Little AM, Madrigal JA, Goldman JM. Severe allergic reaction with anaphylaxis to G-CSF (lenograstim) in a healthy donor. Bone Marrow Transplant. 2009;44(2):129–30. https://doi.org/10.1038/bmt.2008.438.

    Article  CAS  PubMed  Google Scholar 

  89. Engler RJ, Weiss RB. Immediate hypersensitivity to human recombinant granulocyte-macrophage colony-stimulating factor associated with a positive prick skin test reaction. Ann Allergy Asthma Immunol. 1996;76(6):531–4.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oregon Health and Science University, Portland, OR, USA

    Shyam R. Joshi MD

  2. Department of Internal Medicine, Division of Allergy & Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8859, USA

    David A. Khan MD

Authors
  1. Shyam R. Joshi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Khan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Khan MD.

Ethics declarations

Conflict of Interest

Dr. Khan reports other from Genentech, other from Aimmune, outside the submitted work. Shyam R. Joshi declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Anaphylaxis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joshi, S.R., Khan, D.A. Anaphylaxis Induced by Biologics. Curr Treat Options Allergy 6, 125–141 (2019). https://doi.org/10.1007/s40521-019-00207-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40521-019-00207-0

Keywords

Search

Navigation